Biotechnology Law Report


ISSN: 0730-031X        年代:1999
当前卷期:Volume 18  issue 1     [ 查看所有卷期 ]

年代:1999
 
     Volume 18  issue 1
     Volume 18  issue 2   
     Volume 18  issue 3   
     Volume 18  issue 4   
     Volume 18  issue 5   
     Volume 18  issue 6   
1. Foreword
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  1-2

Preview   |   PDF (182KB)

2. {BLR 2819} Changing Intellectual Property Issues in the Biotechnology Industry
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  3-13

JOHN H. BARTON,  

Preview   |   PDF (1971KB)

3. {BLR 2820} The Effect of WLF v Friedman on Product Liability of Prescription Drug Manufacturers
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  14-23

BONNIE LUTZ,  

Preview   |   PDF (1682KB)

4. {BLR 2821} The EB-5 "Employment-Creation" Immigrant Visa for Investors as a Potential Source of Financing for Biotechnology Companies
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  24-40

STELLA BLOOM,  

Preview   |   PDF (3092KB)

5. {BLR 2823} FDA-Heart Disease-PTI-Soy Protein
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  41-41

Preview   |   PDF (127KB)

6. {BLR 2825} ESRD-GelTex-Genzyme
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  42-42

Preview   |   PDF (155KB)

7. {BLR 2829} Aronex-Leukemia-Tretinoin
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  43-44

Preview   |   PDF (298KB)

8. {BLR 2831} Bion Diagnostic-Bladder Cancer-Breast Cancer-Eggs-HER-2-MeridianDiagnostics-Neogen-Vysis-Water-Borne Illness
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  44-45

Preview   |   PDF (307KB)

9. {BRL 2832} Angiogenesis-Coronary Artery Disease-Glioma-Prostate Cance-RAC-Research Subjects
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  45-128

Preview   |   PDF (9159KB)

10. {BLR 2833} AIDS-AltaRex-Amarillo Biosciences-Amgen-Angiogenesis-Aphton-Apoptosis-Aronex-Avant Irrurtunotherapeutics-AviBiopharma-Aviron-BioMarin-Biomira-BioTransplant-Biricodar-Breast Cancer-Burns-Cell Genesys-Cell Therapeutics-Cel-trix-Chiron-Combretastatin-Coulter Phamaceutical-Diarrhea-Enzon-FGF-2-Genentech-Genzyme General-Gilead Sciences-Glyko Biomedical-GVHD-hCG-Hepatitis B-HGS-Idec-IGF-I-Immunex-Inex-Intellivax-Interferons-JanssenPharmac euticals-Leuvectin-Ligand Pharmaceuticals-Lisofylline-Lysosomal Storage Diseases-Mabs-Masamine-Maxia-Maxim Pharmaceuticals-Medeva-Medlrnrnune-MGIF-Myelos-Neurobiological Technologies-Neuropathy-Non-Hodgkin's Lymphoma-Osteoporosis-Osteoprotegerin-Oxigene-Pancreatic Cancer-Parainfluenza Virus-Pasteur Merieux-Procept-Pro-Script-Prostate Cancer-Renal Cell Carcinoma-Retinoids-Rheumatoid Arthritis-Ribozyme Pharmaceuticals-Ribozymes-Rituximab-Rotavirus-Seattle Genetics-Sexually Transmitted Diseases-Shaman Pharmaceuticals-Shigellosis-SmithKline Beecham-Sugen-Triangle Pharmaceuticals-Vaccines-Vascular Genetics-Vertex Pharmaceuticals-Vical
  Biotechnology Law Report,   Volume  18,   Issue  1,   1999,   Page  47-52

Preview   |   PDF (1057KB)

首页 上一页 下一页 尾页 第1页 共20条